The clinical utilization of albuminuria as a surrogate measure of cardiovascular disease burden and risk for events: Are we there yet?

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 1, 2005, Pages 39-41

  Weir, Matthew R ^a   Blantz, Roland C ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CAPILLARY PRESSURE; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE MARKER; HUMAN; KIDNEY FAILURE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ALBUMINURIA; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 12144249550     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200501000-00007     Document Type: Review

References (15)

1. Weir MR. Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor. J Clin Hypertens 2004; 6:134-141.
2. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984; 108:1347-1352.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
6. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
7. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
8. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
9. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
10. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria during antihypertensive treatment translates to reduction in cardiovascular risk in patients with hypertension and ECG-verified left ventricular hypertrophy. A LIFE study. Hypertension 2004 (in press).
11. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60:1131-1140.
12. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65:2309-2320.
13. Atkins RC, Briganti EM, Wiegmann TB. Effect of baseline proteinuria and change in proteinuria with treatment on the risk of renal endpoints in the irbesartan diabetic nephropathy trial (IDNT) [abstract]. J Am Soc Nephrol 2002; 13:7A.
14. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921-927.
15. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33:1004-1010.